Clinical trial · Interventional
Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients
Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial
NCT07598214CI-TRIAL-00112136Dios/Hes-PTrecruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| diosmin/hesperdin | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- control
- description
- patients will take no intervention
- interventionNames
- Combination Product: diosmin/hesperdin
Primary outcomes (2)
- measure
- serum creatinine level
- timeFrame
- 6 months following treatment
- description
- Serum creatinine will be measured in mg/dl every 2 weeks during the study period.
- measure
- blood urea level
- timeFrame
- 6 months following treatment
- description
- blood urea levels will be measured in mg/dl every 2 weeks during the study period.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy. Exclusion Criteria: * -History of allergic reactions attributed to drugs in the study. * Pregnant women. * Life expectancy less than 6 months * Inability or unwillingness to comply with research protocols. * Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min) * Preexisting hearing loss. * Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.
References
Publications (0)
Data not yet available
No reference posted for this study.